Delving into the Latest Updates on Sixera Pharma AB with Synapse

概览

关联

4

项与 Sixera Pharma AB 相关的临床试验

CTIS2023-507743-11-00 / Recruiting

A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-in-human (FIH) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applied SXR1096 cream in patients with Netherton syndrome (NS) - SXR001

开始日期2022-02-21

申办/合作机构

Sixera Pharma AB初创企业

EUCTR2021-003210-39-AT / Not yet recruiting临床1/2期

A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-in-man (FTIM) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applied SXR1096 skin cream in patients with Netherton syndrome (NS)

开始日期2022-02-01

申办/合作机构

Sixera Pharma AB初创企业

NCT05211830 / Unknown status临床1/2期

A Phase I/II, Multicenter, Randomized, Double-blind, Placebo Within-patient Controlled, First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS)

In this phase I/II trial a topical skin cream with the active substance SXR1096 will be tested in patients with Netherton syndroms, a rare inflammatory skin disease. SXR1096 is a specific and potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 - all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be treated for one month with active cream and placebo cream at different areas of the skin.

开始日期2021-12-07

申办/合作机构

Sixera Pharma AB初创企业

100 项与 Sixera Pharma AB 相关的临床结果

登录后查看更多信息

0 项与 Sixera Pharma AB 相关的专利（医药）

登录后查看更多信息

100 项与 Sixera Pharma AB 相关的药物交易

登录后查看更多信息

100 项与 Sixera Pharma AB 相关的转化医学

登录后查看更多信息